Biocon's Syngene, BMS Extend Drug Collaboration Another Five Years
This article was originally published in PharmAsia News
Executive Summary
Biocon's Syngene International unit and Bristol-Myers Squibb have agreed to extend their collaboration on drug discovery for another five years to build on their success with six drug molecules under the old work agreement.